Maintenance infliximab therapy in patients with Crohn's disease: how long, how much, how frequent?
Cuffari
Carmen
C
Lichtenstein
Gary R
GR
D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D000917:Antibody Formation; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000008:administration & dosage*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D000069285:Infliximab; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab